Cargando…

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer

BACKGROUND: Neoadjuvant chemoradiation therapy (CRT) is a widely used preoperative treatment strategy for locally advanced rectal cancer (LARC). However, a few studies have evaluated the molecular changes caused by neoadjuvant CRT in these cancer tissues. Here, we aimed to investigate changes in imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Incheol, Lee, Hye Won, Byun, Sang Jun, Park, Jee Young, Min, Hyeonji, Lee, Sung Hwan, Lee, Ju-Seog, Kim, Shin, Bae, Sung Uk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949478/ https://www.ncbi.nlm.nih.gov/pubmed/33692216 http://dx.doi.org/10.1136/jitc-2020-001610

Ejemplares similares

Intrahepatic inflammatory IgA(+)PD-L1(high) monocytes in hepatocellular carcinoma development and immunotherapy
por: Sung, Pil Soo, et al.
Publicado: (2022)

Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer
por: Wilkins, Anna, et al.
Publicado: (2021)

Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition
por: Yu, Anze, et al.
Publicado: (2023)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

CD8(+) TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens
por: Lee, Sung-Woo, et al.
Publicado: (2021)

Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer
por: Kim, Miok, et al.
Publicado: (2021)

Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis
por: Xing, Xiaofang, et al.
Publicado: (2022)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
por: Posner, Atara, et al.
Publicado: (2023)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
por: Kelly, Andrew D, et al.
Publicado: (2021)

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
por: Chen, Xiaofeng, et al.
Publicado: (2021)

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
por: Negrao, Marcelo V, et al.
Publicado: (2021)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer
por: Bai, Yuezong, et al.
Publicado: (2022)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
por: Qin, Yong, et al.
Publicado: (2020)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy
por: Shi, Lin, et al.
Publicado: (2023)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
por: Mao, Jinzhu, et al.
Publicado: (2021)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
por: Weng, Jialei, et al.
Publicado: (2023)

Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets
por: Oldham, Robyn A A, et al.
Publicado: (2020)

Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response
por: LaSalle, Thomas, et al.
Publicado: (2020)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
por: Hwang, Michael, et al.
Publicado: (2022)

Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity
por: Sorin, Mark, et al.
Publicado: (2023)

Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy
por: Yin, Xuewen, et al.
Publicado: (2023)

Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study
por: Huang, Weicai, et al.
Publicado: (2023)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)

Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions
por: Abdulrahman, Ziena, et al.
Publicado: (2022)

Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer
por: Guo, Yongdong, et al.
Publicado: (2023)

Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
por: Decazes, Pierre, et al.
Publicado: (2023)

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
por: Ager, Casey R, et al.
Publicado: (2023)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f5bd3mpmt5j082i3gm4mi17m6k